The microbial ecosystems within our mouths may affect our cognitive function as we age, according to a study. Interventions such as prebiotics, including dietary nitrate, have potential for delaying cognitive decline.
About 15% of older adults have mild cognitive impairment, which is the largest risk factor for the development of dementia or Alzheimer’s disease. There is a known association between periodontitis—gum disease—and worsened cognitive function. Researchers have identified two possible links between the mouth and the mind: pathogenic oral bacteria could enter the bloodstream and move to the brain, or pathogenic oral bacteria could displace nitrate-reducing bacteria, which help create nitric oxide the brain needs for synaptic plasticity and long-term potentiation. Anni Vanhatalo and colleagues characterized the oral microbiome of 115 participants, 55 of whom had mild cognitive impairment. Some participants had the apolipoprotein E4 (APOE4) allele, which increases risk for cognitive decline and Alzheimer’s disease. A high relative abundance of bacteria in the genus Neisseria was associated with better executive function and visual attention within the mild cognitive impairment group. Among healthy participants, Neisseria correlated with working memory. High prevalence of bacteria in the genus Porphyromonas predicted mild cognitive impairment status, while Prevotella intermedia predicted APOE4-carrier status. According to the authors, diet can affect the oral microbiome, and a nitrate-rich diet (such as the Mediterranean and ‘Dietary Approaches to Stop Hypertension’ diets), favors bacteria associated with good cognitive outcomes.
Journal
PNAS Nexus
Article Title
Oral microbiome and nitric oxide biomarkers in older people with mild cognitive impairment and APOE4 genotype
Article Publication Date
28-Jan-2025
COI Statement
J.E.L., D.V., B.C., P.G.W., A.M.J., A.V. declare no competing interests. C.B. has received consulting fees from Acadia pharmaceutical company, AARP, Addex pharmaceutical company, Eli Lily, Enterin pharmaceutical company, GWPharm, H. Lundbeck pharmaceutical company, Novartis pharmaceutical company, Janssen Pharmaceuticals, Johnson and Johnson pharmaceuticals, Novo Nordisk pharmaceutical comapny, Orion Corp pharmaceutical company, Otsuka America Pharm. Inc, Sunovion Pharm. Inc, Suven pharmaceutical company, Roche pharmaceutical company, Biogen pharmaceutical company, Synexus clinical research organization and tauX pharmaceutical company and research funding from Synexus clinical research organization, Roche pharmaceutical company, Novo Nordisk pharmaceutical company and Novartis pharmaceutical company. A.C. discloses financial relationships with Suven and Janssen pharmaceutical companies for consultancy work.